Börskollen - Aktier, fonder och ekonominyheter
Börskollen
Erbjudande: Axvik till börsen med stark tillväxt inom flyg och försvar – nu kan du teckna (annons)

Analyser av Prolight Diagnostics

Kurs från TradingView
Visa mer ▼
StartNyheterPressreleaserRiktkurserInsynshandelBlankningAnalyserBloggarVideosPodcasts

Prolight: Financing and partner interest strengthen case ahead of regulatory study - Emergers

In Q2, Prolight reported initial positive data from its ongoing whole blood study at St Thomas’ Hospital in London, showing equivalence betw...

Emergers • 29 aug 2025 08:18

Prolight: Fully subscribed rights issue strengthens Psyros case ahead of commercial partnerships - Emergers

Prolight announced that its rights issue was fully subscribed, eliminating near-term financing risk and securing the capital needed to final...

Emergers • 03 jul 2025 09:19

Prolight Diagnostics: Positive patient data and patent approval strengthen case for Psyros - Emergers

Key milestone for readiness Prolight has reported positive interim results from the ongoing patient blood study at St Thomas’ Hospital in Lo...

Emergers • 18 jun 2025 08:29

Prolight Diagnostics: Gearing up for commercialisation with strong insider backing - Emergers

Strong insider commitment signals confidence As expected, Prolight has now announced a rights issue of SEK 100m to finance the development o...

Emergers • 23 maj 2025 11:21

Prolight: Positive results from the pre-clinical validation study de-risk the full clinical validation - Emergers

Following the many recent grants, notices of allowance and intention to grant patents in Europe and the US, and the arrival of the first of ...

Emergers • 01 apr 2025 09:38

Prolight: SpinChip deal highlights the strategic importance and valuation potential of Prolight's solution - Emergers

The recent acquisition of Norwegian point-of-care diagnostics platform SpinChip by bioMérieux for EUR 138 million underscores the growing in...

Emergers • 20 jan 2025 09:28

Prolight: Commercial prototype marks an important milestone towards upcoming studies - Emergers

The arrival of the first commercial prototype instruments for Prolight’s Psyros Point of Care (POC) system marks an important development mi...

Emergers • 03 dec 2024 13:56

Prolight: Advancing with strengthened financials towards clinical performance study in 2025 - Emergers

Prolight continues to make progress with its proprietary Psyros platform, with a pre-validation study, including fresh blood samples from 12...

Emergers • 28 nov 2024 08:06

Prolight: Pre-validation readout in Q4 sets stage for multicenter trial in 2025 - Emergers

Supported by the latest troponin data generated from whole blood samples on the final commercial cartridge design, Prolight is now ready to ...

Emergers • 29 aug 2024 09:07

Prolight Diagnostics: SEK 17m UK grant a welcome external validation - Emergers

Prolight’s report for Q1’24 did not reveal any particular surprises.

Emergers • 20 maj 2024 10:31

Prolight Diagnostics: Bra slagläge för hjärtbiomarkörtest - Mangold

Mangold Insight inleder bevakning av medicinteknik-bolaget Prolight Diagnostics med rekommendationen Köp.

Mangold • 26 apr 2024 10:48

Prolight Diagnostics: PoC troponin testing ready for next step - Emergers

There has been a somewhat mixed news flow from Prolight after the close of Q1’24.

Emergers • 25 apr 2024 09:35

Prolight: Important milestone amidst mixed news flow - Emergers

There has been a somewhat mixed news flow from Prolight after the close of Q1’24.

Emergers • 25 apr 2024 09:12

Prolight Diagnostics: PoC troponin testing ready for next step - Emergers

With proof-of-performance for its proprietary digital technique for detection of high-sensitive biomarkers even in whole blood, Prolight has...

Emergers • 23 feb 2024 10:38

Prolight Diagnostics: Single molecule biomarker POC test upcoming - Emergers

Having already achieved proof-of-performance for its proprietary digital technique for detection of high-sensitive biomarkers in low concent...

Emergers • 05 feb 2024 09:45